Skip to main content
Livermore
Livermore
ZHEN

Morgan Stanley

SEC CIK
0000895421
Latest filing
Aug 13, 2026

EOCN holding history

Galmed Pharmaceuticals Ltd. in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

EOCN overviewAll 13F holders of EOCNFull Q2 2026 holdings

Shares (Q2 2026)
56
Value
$31
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of EOCN by Morgan Stanley, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202656$31<0.1%−101−64.3%ReducedHolders
Q1 2026157$77<0.1%−141−47.3%ReducedHolders
Q4 2025298$224<0.1%+200+204.1%AddedHolders
Q3 202598$135<0.1%−33,475−99.7%ReducedHolders
Q2 202533,573$61.8K<0.1%+26,188+354.6%AddedHolders
Q1 20257,385$10.6K<0.1%−5,145−41.1%ReducedHolders
Q4 202412,530$40.0K<0.1%+12,426+11,948.1%AddedHolders
Q3 2024104$713<0.1%−36,109−99.7%ReducedHolders
Q2 202436,213$9.96K<0.1%+21,715+149.8%AddedHolders
Q1 202414,498$5.02K<0.1%−67,970−82.4%ReducedHolders
Q4 202382,468$37.5K<0.1%+62,436+311.7%AddedHolders
Q3 202320,032$12.4K<0.1%+7,534+60.3%AddedHolders
Q2 202312,498$37.4K<0.1%−1,118−8.2%ReducedConverted for a 1-for-15 splitHolders
Q1 2023204,245$87.1K<0.1%+23,521+13.0%AddedHolders
Q4 2022180,724$90.4K<0.1%−8,896−4.7%ReducedHolders
Q3 2022189,620$59.0K<0.1%−6,079−3.1%ReducedHolders
Q2 2022195,699$127.0K<0.1%+30,399+18.4%AddedHolders
Q1 2022165,300$263.0K<0.1%+4,500+2.8%AddedHolders
Q4 2021160,800$293.0K<0.1%−3,700−2.2%ReducedHolders
Q3 2021164,500$459.0K<0.1%−19,700−10.7%ReducedHolders
Q2 2021184,200$560.0K<0.1%−1,352−0.7%ReducedHolders
Q1 2021185,552$636.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.